SQLite Web: event

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-21T12:20:48.730501+00:00","dedupe_key":"signal_enriched:discovery_unusual_volume_delta:d9ad88995ac9c10f","evidence_event_ids":["evt_6d17a12950eb"],"signal_type":"discovery_unusual_volume_delta","source":"discovery_ingestor","value":{"aggregator_url":"https://www.nasdaq.com/articles/monthly-weight-loss-shot-why-pfizer-could-topple-lillys-and-novos-glp-1-duopoly","as_of":"2026-04-21T12:20:48.730501+00:00","canonical_url":"https://www.fool.com/investing/2026/04/21/a-monthly-weight-loss-shot-why-pfizer-could-topple/","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/monthly-weight-loss-shot-why-pfizer-could-topple-lillys-and-novos-glp-1-duopoly","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_252475091c71cf6e","canonical_host":"fool.com","canonical_is_aggregator":false,"canonical_url":"https://www.fool.com/investing/2026/04/21/a-monthly-weight-loss-shot-why-pfizer-could-topple/","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-21T22:33:08.416354+00:00","extraction_method":"trafilatura","fetched_description":"Key PointsNovo Nordisk and Eli Lilly are largely responsible for creating today's weight-loss drug market.","fetched_title":"A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly | Nasdaq","final_url":"https://www.nasdaq.com/articles/monthly-weight-loss-shot-why-pfizer-could-topple-lillys-and-novos-glp-1-duopoly","html_truncated":false,"paywall_likely":false,"publisher_domain":"fool.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/monthly-weight-loss-shot-why-pfizer-could-topple-lillys-and-novos-glp-1-duopoly","source_event_id":"evt_6d17a12950eb","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"88dea56b0bea63fc","kind":"unusual_volume","published_at":"2026-04-21T11:50:00+00:00","publisher_domain":"fool.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.72,"dates_mentioned":["2017","mid-2021","2021","2023","2025","November","Q4 (last year)","early 2024","2026","week 28","64-week regimen"],"entities":[{"asset_class":"equity","name":"Pfizer","relevance":"high","symbol":"PFE","type":"company"},{"asset_class":"equity","name":"Novo Nordisk","relevance":"high","symbol":"NVO","type":"company"},{"asset_class":"equity","name":"Eli Lilly","relevance":"high","symbol":"LLY","type":"company"},{"asset_class":"other","name":"PF-08653944 (PF\u20193944)","relevance":"high","symbol":"","type":"drug_candidate"},{"asset_class":"other","name":"Wegovy (semaglutide)","relevance":"medium","symbol":"","type":"drug"},{"asset_class":"other","name":"Zepbound (tirzepatide)","relevance":"medium","symbol":"","type":"drug"}],"event_type":"other","information_gaps":["The provided signal type is discovery_unusual_volume_delta, but the text contains no volume data, no volume ratio vs average, and no confirmation of unusual trading volume.","The article excerpt does not explicitly state whether any volume spike is confirmed by news; it is primarily a competitive/clinical narrative.","No explicit catalyst is tied to a specific trading-volume event; the most likely catalyst hypothesis is inferred from the article\u2019s discussion of Phase 2b results and monthly dosing potentially increasing competitive pressure."],"key_facts":["Novo Nordisk and Eli Lilly are described as dominating the anti-obesity drug market and as having created the current market structure.","FDA approval timeline stated: Wegovy approved for weight loss in mid-2021; Zepbound approved in 2023.","Pfizer\u2019s GLP-1 focused drug PF-08653944 (PF\u20193944) is described as performing well in Phase 2b trials.","Phase 2b efficacy claim: by week 28 of a planned 64-week regimen, weight loss of 10%\u201312% is described as the norm for low and medium doses.","Dosing claim: PF\u20193944 is described as requiring monthly rather than weekly subcutaneous injections to achieve comparable weight loss.","The article claims weekly dosing is a barrier, with at least half (up to two-thirds) of GLP-1 users discontinuing within a year, citing cost.","The article states Wegovy prescriptions declined before end of 2025 despite a price drop for self-pay users in November.","The article claims Novo expects its top and bottom lines to sink 5%\u201313% this year due largely to weakness from its weight-loss drug business.","The article states Zepbound revenue grew 175% last year from $4.9B to $13.5B, but also says growth was slowing by Q4 and lower realized prices took a toll.","The article states both NVO and LLY stocks are down since the beginning of the year due to disappointing anti-obesity growth and guidance, and describes a price war after Zepbound availability.","The article says Pfizer is planning Phase 3 testing based on Phase 2b findings and is already planning more than 20 anti-obesity trials for 2026, including 10 Phase 3 trials of PF\u20193944.","The article suggests only a handful of successful tests could be enough to turn the market into a low-margin, commodity-like business."],"numeric_claims":[{"label":"weight_loss_by_week_28_percent","value":"10%\u201312%"},{"label":"planned_regimen_length_weeks","value":"64"},{"label":"discontinuation_within_1_year","value":"at least 50% to up to 66%"},{"label":"Novo_expected_top_bottom_line_change_percent","value":"-5% to -13%"},{"label":"Zepbound_revenue_growth_percent","value":"175%"},{"label":"Zepbound_revenue_start_$B","value":"$4.9B"},{"label":"Zepbound_revenue_end_$B","value":"$13.5B"},{"label":"number_of_anti_obesity_trials_planned_for_2026","value":"more than 20"},{"label":"number_of_Phase_3_trials_of_PF\u20193944_in_2026","value":"10"}],"primary_claim":"Pfizer\u2019s PF-08653944 Phase 2b results show 10%\u201312% weight loss by week 28 with monthly (not weekly) subcutaneous injections, which the article suggests could pressure Novo and Lilly\u2019s pricing power.","relevance_score":0.55,"sentiment":"mixed","source_quality":"high","summary":"The article argues Pfizer\u2019s GLP-1 candidate PF-08653944 (PF\u20193944) could disrupt the Novo Nordisk/Eli Lilly anti-obesity duopoly by offering comparable weight loss with monthly injections. It frames this as a potential catalyst for increased competition and further pricing pressure.","topics":["GLP-1","anti-obesity drugs","Pfizer pipeline","Novo Nordisk","Eli Lilly","pricing pressure","Phase 2b results","monthly vs weekly dosing"]},"source":"Nasdaq Markets","source_domain":"fool.com","summary":"Key PointsNovo Nordisk and Eli Lilly are largely responsible for creating today's weight-loss drug market.","tickers":[],"title":"A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly","url":"https://www.fool.com/investing/2026/04/21/a-monthly-weight-loss-shot-why-pfizer-could-topple/"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

event_store.db — events

Update row 474380 in events